ArticleWorld journal of gastroenterology2019
Tailored eradication
Article in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Pooled it
- Guideline
- Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-ResistantGut and liver · 2022Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- Eradication rates of Helicobacter pylori regimens and predictors of treatment failure: A multicenter real-world study in Saudi Arabia.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Systematic Evaluation of Helicobacter pylori Susceptibility to Antibiotics Before First-Line Treatment: A Cohort Study.United European gastroenterology journal · 2025Article
- Tailored therapy guided by genotypic resistance from gastric mucosa samples in the first-line treatment ofTherapeutic advances in gastroenterology · 2025Article
- Antimicrobial drug susceptibility testing for the management ofFrontiers in microbiology · 2025Review
- Efficacy of 7-day Tailored Therapy forThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- Antibiotic Resistance, Susceptibility Testing and Stewardship inInternational journal of molecular sciences · 2023Review
- Real-Time Polymerase Chain Reaction: Feed Two Birds with One Seed?Gut and liver · 2023Article
- Current guidelines forWorld journal of clinical cases · 2022Review
- Empirical vs. Susceptibility-Guided Treatment ofFrontiers in microbiology · 2022Article
- Tailored eradication strategyWorld journal of gastroenterology · 2021Article
- Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes forGut and liver · 2021Article
- Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients withJournal of clinical medicine · 2021Article
- The status and progress of first-line treatment againstTherapeutic advances in gastroenterology · 2021Review
- Empirical or susceptibility-guided treatment forTherapeutic advances in gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew studies have compared the efficacy and safety profile of a tailored eradication (TR) strategy based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple therapy (EBQT) for first-line eradication of
aimTo compare the efficacy and safety of a TR strategy and those of EBQT regimen as first-line eradication therapy for
methodsThis is an open-label, comparative study in which we prospectively enrolled patients over 18 years of age with
resultsA total of 150 patients were assigned to the TR (
conclusionDPO-PCR-based TR for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.